Clicky

Epigenomics AG(ECX)

Description: Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Biomarkers Colorectal Cancer Molecular Diagnostics Hepatocellular Carcinoma Biopsy Epi Epigenomics Ag Liquid Biopsy

Home Page: www.epigenomics.com

Geneststrasse 5
Berlin, 10829
Germany
Phone: 49 30 243 450


Officers

Name Title
Mr. Gregory K. Hamilton CEO & Member of the Exec. Board
Dr. Andrew A. Lukowiak Ph.D. Pres & Chief Scientific Officer
Mr. Jens Ravens CFO & Member of Exec. Board
Frederic Hilke Investor Relations Officer
Dr. Noel Thomas Doheny Chief Exec. Officer of Epigenomics Inc.

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4086
Price-to-Sales TTM: 10.8103
IPO Date:
Fiscal Year End: December
Full Time Employees: 36
Back to stocks